Previous close | 0.00 |
Open | 0.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 420 |
Market cap | N/A |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Ecully, October 24, 2023 NET SALES AS OF SEPTEMBER 30, 2023 PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales as of September 30, 2023. The PCAS Group has generated consolidated net sales of €151.9 million as of September 30, 2023, a 2,7% decrease compared to the same period during the previous financial year (-2.8% at constant exchange rates). In millio
+ Ecully, September 6, 2023 RESULTS AS OF JUNE 30, 2023 PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated results as of June 30, 2023, approved by today’s Board of Directors. 30 June 2022 30 June 2023 in millions of euros Net sales 109.8 113.4 EBITDA (*) -0.5 4.7 EBITDA margin -0.5% 4.2% Current operating income (*) -15.3 -11.0 Parmaceutical Synthesis -18.7 -18.3
Ecully, July 27, 2023 NET SALES AS OF JUNE 30, 2023 PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales as of June 30, 2023. The PCAS Group has generated consolidated net sales of €113.4 million as of June 30, 2023, a 3.3% increase compared to the same period during the previous financial year (+2.9% at constant exchange rates). In millions of euros 2023 2